The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 11, 2017

Filed:

Apr. 25, 2016
Applicant:

Daiichi Sankyo Company, Limited, Chuo-ku, Tokyo, JP;

Inventors:

Gilles Bernard Tremblay, La Prairie, CA;

Mario Filion, Longueuil, CA;

Matthew Stuible, Mont-Royal, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/11 (2006.01); C12N 15/13 (2006.01); C12N 15/63 (2006.01); C07K 16/28 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); A61K 47/48561 (2013.01); C07K 16/30 (2013.01); G01N 33/57407 (2013.01); G01N 33/6893 (2013.01); C07K 2316/96 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); G01N 2800/108 (2013.01);
Abstract

Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies. Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.


Find Patent Forward Citations

Loading…